Correspondence 0000950170-23-024532 from Tracon Pharmaceuticals, Inc. (TCON) (CIK 0001394319)
Tracon Pharmaceuticals, Inc. (TCON) (CIK 0001394319)
Date: May 26, 2023 · CIK: 0001394319 · Accession: 0000950170-23-024532
AI Filing Summary & Sentiment
File numbers found in text: 333-272100
Letter
TRACON Pharmaceuticals, Inc.
4350 La Jolla Village Drive, Suite 800
San Diego, California 92122
May 26, 2023
Via EDGAR
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Doris Stacey Gama
RE: TRACON Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed on May 19, 2023
File No. 333-272100
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective at 4:01 p.m. Eastern Time on May 31, 2023, or as soon thereafter as is practicable.
Once the above-referenced Registration Statement has been declared effective, please orally confirm that event with Matthew Browne of Cooley LLP, counsel to the undersigned registrant, at (858) 550-6045.
TRACON Pharmaceuticals, inc.
By: /s/ Scott Brown
Scott Brown
Chief Financial Officer
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
TRACON Pharmaceuticals, Inc.
4350 La Jolla Village Drive, Suite 800
San Diego, California 92122
May 26, 2023
Via EDGAR
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Doris Stacey Gama
RE: TRACON Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed on May 19, 2023
File No. 333-272100
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective at 4:01 p.m. Eastern Time on May 31, 2023, or as soon thereafter as is practicable.
Once the above-referenced Registration Statement has been declared effective, please orally confirm that event with Matthew Browne of Cooley LLP, counsel to the undersigned registrant, at (858) 550-6045.
TRACON Pharmaceuticals, inc.
By: /s/ Scott Brown
Scott Brown
Chief Financial Officer